MktsMarkets

Marker Therapeutics, Inc.
NASDAQ: MRKRKey statistics
MRKR News
Stories mentioning MRKR from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 2,843 | 2,141 | 2,346 | 4,177 | 3,135 | 5,087 | 3,471 | 2,335 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 4,073 | 2,987 | 3,370 | 5,122 | 4,958 | 6,113 | 4,326 | 3,477 |
| Operating Income (Loss) | (4,073) | (1,534) | (2,137) | (4,261) | (4,958) | (3,861) | (2,400) | (2,308) |
| Interest Income | 133.00 | 166.00 | 138.00 | 128.00 | 162.00 | 74.00 | 92.00 | 115.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (3,179) | (1,703) | (1,999) | (4,016) | (4,446) | (3,837) | (2,308) | (2,193) |
| Earnings Per Share (Basic) | (0.16) | (0.11) | (0.12) | (0.29) | (0.40) | (0.43) | (0.26) | (0.25) |
| Earnings Per Share (Diluted) | (0.16) | (0.11) | (0.12) | (0.29) | (0.40) | (0.43) | (0.26) | (0.25) |
| Weighted Average Shares Outstanding (Basic) | 19,315 | 15,310 | 16,758 | 13,957 | 11,106 | 8,980 | 8,923 | 8,918 |
| Weighted Average Shares Outstanding (Diluted) | 19,315 | 15,310 | 16,758 | 13,957 | 11,106 | 8,980 | 8,923 | 8,918 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About MRKR
Marker Therapeutics, Inc. (NASDAQ: MRKR) is a stock listed on the Nasdaq Stock Market under the ticker symbol MRKR. It last traded at $1.09 (Nov 20, 2026, 4:00 PM ET), down 17.4% on the day. That gives Marker Therapeutics a market capitalisation of $18.3M.
Over the past 52 weeks MRKR has traded between $0.8100 and $2.46.
For the quarter ended Mar 31, 2026 it reported a net loss of $3.2M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$3.2M |
| Dec 31, 2025 | — | -$1.7M |
| Sep 30, 2025 | — | -$2.0M |
| Jun 30, 2025 | — | -$4.0M |
From Marker Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…